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Complex micro- and nano-structures enable crucial developments in the healthcare remit
(e.g., pharmaceutical and biomaterial sciences). In recent times, several technologies have been
developed and explored to address key healthcare challenges (e.g., advanced chemotherapy, biomedical
diagnostics and tissue regeneration). Electrohydrodynamic atomization (EHDA) technologies are
rapidly emerging as promising candidates to address these issues. The fundamental principle driving
EHDA engineering relates to the action of an electric force (field) on flowing conducting medium
(formulation) giving rise to a stable Taylor cone. Through careful optimization of process parameters,
material properties and selection, nozzle and needle design, and collection substrate method, complex
active micro- and nano-structures are engineered. This short review focuses on key selected recent and
established advances in the field of pharmaceutical and biomaterial applications.Introduction
Complex micro- and nano-structures are enabling crucial devel-
opments in the healthcare remit (e.g., pharmaceutical sciences),
which also demonstrates a shift from conventional coarser and
simple technologies. Deviation from established concepts and
methodologies relating to drug delivery or biomaterial develop-
ment is testing and initially met with reservation. However, high-
value developments that can overcome barriers for existing con-
cepts or methods, and are able to address key global challenges, are
recognizable through research impact and utility. For emerging
enabling platform technologies, concept development and novel
structure engineering outcomes are achievable in tandem, provid-
ing numerous opportunities in technological advances. The phar-
maceutical and biomaterial industries are well accustomed withCorresponding author: Ahmad, Z. (zahmad@dmu.ac.uk)
1359-6446/Crown Copyright  2016 Published by Elsevier Ltd. This is an open access article under the CC B
http://dx.doi.org/10.1016/j.drudis.2016.09.021 established micro- and nano-engineering platforms such as spray-
drying, freeze-drying, super critical fluid synthesis and microflui-
dics. Over the past two decades, electrohydrodynamic atomization
(EHDA) technologies have been explored in great depth evidenced
by the exponential growth in related research article publications.
Developments within this technology are also embracing timely
areas such as biomedical imaging, regenerative medicine, 3D
printing and advanced drug delivery as well as providing much
needed complexity to the fiber and particle communities. Further-
more, the technologies are attractive because the processes are
facile, one-step, versatile and are operational at ambient condi-
tions, and yield complex nano- and micro-structures pertinent to
an array of pharmaceutical and biomaterial applications. These
also offer significant advantages over existing technologies that
are unsuitable for several materials (e.g., owing to elevated process
temperatures and shear stresses) [1] that can compromise theY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.drugdiscoverytoday.com 157
REVIEWS Drug Discovery Today  Volume 22, Number 1  January 2017
R
eview
s
P
O
S
T
S
C
R
E
E
Nfunctionality of biomaterials (e.g., proteins) or active pharmaceu-
tical ingredients (APIs) [1–3].
The underlying principle of EHDA processes is based on utiliz-
ing an electrical force to atomize liquids; which electrically
imposes (electro) a liquid (hydro) jet (dynamic) out of a liquid-
filled (infused) nozzle in the form of a jet. Jetting behavior and
process parameters predominantly enable particle or fiber synthe-
sis – the simplest form of EHDA engineering. These architectures
can then be collected onto an electrically grounded substrate
positioned under the tip of the nozzle. The production of a variety
structures can be achieved by varying processing parameters (for-
mulation flow or infusion rate, applied voltage and deposition
distance) and physical properties of the liquid (viscosity, density,
surface tension and electrical conductivity). Materials for formu-
lation development are often characterized for such properties
because these significantly affect jetting stability [4] as well as
morphology and phase of engineered structures [5].
EHDA jets are established and characterized by evaluating two
parameters: intensity and droplet diameter (both of which are
affected by physical liquid properties and the process parameters).
EHDA modes are classified into two categories (depending on how
the liquid jet breaks up into droplets): (i) dripping mode (occurs
when only fragments of liquid exit from the nozzle); and (ii)
jetting mode (observed when the formulation liquid breaks up
into fine droplets some distance from the nozzle exit) [4] (Fig. 1).
There are two main forms of EHDA processes: electrospraying
(ESy; particle production); and electrospinning (ES; fiber produc-
tion), and they serve as promising enabling technologies for a range
of applications [6]. This review focuses on crucial, and the most
recent, developments in EHDA technologies and their various
applications related to pharmaceutical and biomaterial sciences.
Examples of structures generated using EHDA technologies (single
and co-axial nozzles, printing, multiple nozzles, nonconcentric
nozzles and multiphase generation) are provided. Table 1 sum-
marizes key selected developments in this area. Fig. 2 shows exam-
ples of various structures produced using EHDA technologies.(a) (b)
(c) (d)
2.1  µm
2.1 
2.1 
2.1  µm
FIGURE 1
EHDA jetting examples from a single nozzle system showing: (a) Formulation flow
Taylor cone; (d) multiple-jets from a single nozzle. (e) The coaxial nozzle system use
two pores (nozzle-less approach). Formulation used for jetting examples polycap
158 www.drugdiscoverytoday.comSingle nozzle
The first and simplest EHDA configuration consists of a single
nozzle through which formulation (API–polymer solution) is in-
fused and atomized using an electrical force. The API is typically
incorporated into a polymer–solvent solution, although numer-
ous excipients can also be added to increase complexity or modify
functionality. During the atomization process, which includes
rapid solvent evaporation, the API is uniformly dispersed through-
out the polymeric matrix, which is also a means to enhance the
amorphous form of crystalline drug [7]. The potential of single
nozzle systems has been demonstrated using a large selection of
active biomaterials (e.g., synthetic bone minerals, proteins and
peptides) and the encapsulation of genes and anticancer and other
bioactive agents [8].
Insulin (a hormone produced by the pancreas) was one of the
first biomolecules to be utilized for the ESy process. Near-mono-
dispersed insulin-loaded nanoparticles (NPs) were produced using
a single nozzle system (variable flow rates of 0.17, 0.24 and
0.38 ml/min and applied voltage of 5 kV) sufficient to yield
NPs in the range of 98–117 nm. Gomez et al. found that, by
decreasing the concentration of insulin in solution or by reducing
the flow rate of the ESy system, smaller particles can be generated
[9]. More recently, N-acetylcysteine (NAC)-loaded poly(lactic-co-
glycolic acid) (PLGA) NPs were also synthesized using a single
nozzle ESy technique (flow rate 0.06–0.18 ml/h and applied
voltage 10 kV) [10]. NAC is a thiol-containing compound used
for the treatment of bronchitis, cystic fibrosis, emphysema and
pneumonia with poor oral bioavailability (4–10%). By optimizing
process conditions, resulting particles were as small as 122 nm
with drug encapsulation efficiency (EE) of 54.5%. These were
achieved by reducing the flow rate and matrix polymer (PLGA)
concentration. Particles exhibited a biphasic release profile – an
initial burst release followed by a more sustained release [10].
Other proteins have also been encapsulated to prepare bioma-
terial scaffolds (fibrous structures) using the single nozzle ES
process to facilitate neo-tissue development. Electrospun fibrous(e)
 µm
 µm
(f)
5 mm
10 mm
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 with no applied voltage – dripping; (b) unstable jetting; (c) stable jetting –
d for jetting with two co-flows (inner and outer nozzles). (f) Stable jetting from
rolactone (5% (w/v)) and dichloromethane.
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TABLE 1
A summary of key selected developments in various EHDA technologies.
EHDA method Nozzle/
needle
geometry
Nozzle size
(mm)
Active/
encapsulated
material
Application Particle/fiber
diameter (mm)
Materials
for matrix or
encapsulant
Comments Refs
Electrospraying Single Not specified N-acetylcysteine Amino acid
delivery
0.122 PLGA Box–Behnken design was used to find
optimum parameter settings. Smallest
size and smallest polydipsersity: flow rate
(0.06 ml/h), polymer concentration (0.5%
(w/w)), collecting distance (9.28 cm) and
encapsulation efficiency of 54.5%
[10]
Single 0.55 Cisplatin Anticancer
drug delivery
0.059 Silk fibroin Release of cisplatin was sustained for
more than 15 days. Sufficient apoptosis of
A549 lung cancer cells was observed with
less toxicity to L929 mouse fibroblast cells
[20]
Coaxial Outer
nozzle: 1.9
Inner
nozzle: 0.9
Angiotensin II Peptide
hormone
delivery
0.1–0.3 Tristearin Clear core–shell structure was observed
with triphasic release kinetics; initial burst
followed by sustained and finally
conventional diffusion
[25]
Coaxial Outer nozzle:
ID: 1.0
Inner nozzle:
OD: 0.5
ID: 0.3
Metronidazole Antibiotic 0.06–0.389
(depends on
PMMA
percentage)
PMMA,
EudragitW/RS
The porous hydrophilic core/
hydrophobic shell NPs exhibited slow
release of drug. Capsules maintained
their size for over 8 h as a result of
bioinert nature of PMMA. Cellular
internalization analysis confirmed safety
of the prepared NPs
[29]
Co-axial Outermost:
OD: 4
ID: 3.2
Second
outermost:
OD: 2.6
ID: 2.0
Second
innermost:
OD: 1.5
ID: 1.0
Innermost:
OD:0.5
ID: 0.2
Hermatoxylin
dye, pinacyanol
chloride, pyronin,
Evans blue
Multiple dye
loading and
release
0.620  0.150 PEG, PLGA,
PCL, PMSQ
A four-nozzle device was utilized to
produce four layered particles and fibers.
TEM demonstrated four distinct layers
whereas in vitro release studies indicated
combination of release mechanisms,
dissolution and diffusion
[24]
Single ID: 0.6 Red blood cells Imaging
using
MRI and
fluorescence
0.0044–0.005 EHEC, HPC,
CEC, dextran,
PEG, PMMA
The blood-cell-shaped polymeric
particles were able to pass through
channels that were smaller than the
particles themselves; enabling improved
circulation in blood. Encapsulation of dye
indicates multifunctional capabilities of
these biodegradable particles
[39]
Electrospinning Single Not specified siRNA Gene therapy 0.3–0.4 PCL, PEG Fibers released siRNA for a minimum of
28 days and exhibited 61–81% silencing
efficiency.
[16]
Single OD: 0.64
ID: 0.33
Piroxicam Anti-
inflammatory
action
11.4 No matrix A new polymorph resulted that was
verified by using various spectroscopic
techniques. FTIR showed new chemical
bonds as well as new functional groups
present in the sprayed piroxicam
[21]
Coaxial Outer nozzle: OD: 0.9
Inner nozzle: OD: 0.63
ID: 0.33
Doxorubicin Anticancer
drug delivery
0.284
(mean
diameter of
doxuorubicin-
loaded
micelles-loaded
coaxial NF)
Gelatin, PVA Biodegradable polymeric NFs embedded
with micelles provided another barrier for
drug diffusion, hence providing sustained
release of doxorubicin
[32]
Coaxial Outer nozzle: OD: 1.15
ID: 0.99
Inner nozzle: OD: 0.6
ID:0.3
Doxorubicin Anticancer
drug delivery
0.235 PVA, chitosan Biocompatible NFs had less cytotoxicity
compared with free doxorubicin; whereas
in vitro release experiments showed drug
release rate was controllable. The
resulting fibers also promoted
attachment, proliferation and spreading
of human ovarian cancer cells (SKOV3)
[31]
Coaxial Outer nozzle: OD: 1.5
ID: 1
Inner nozzle: OD: 0.4
ID:0.2
Ketoconazole Antifungal Optimal
8.7  7.2
PCL Hollow PCL fibers loaded with magnetic
Fe3O4 particles and ketoconazole. Release
mainly diffusive but expedited with
external trigger using an auxiliary
magnetic field
[38]
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TABLE 1 (Continued )
EHDA method Nozzle/
needle
geometry
Nozzle size
(mm)
Active/
encapsulated
material
Application Particle/fiber
diameter (mm)
Materials
for matrix or
encapsulant
Comments Refs
Bubbling Coaxial Outer nozzle: OD: 1.1
ID: 0.685
Inner nozzle: OD: 0.3
ID: 0.15
Air Imaging and
drug delivery
potential
Different
sizes
but all
below 10
Phospholipid High yield of MBs (109 bubbles/min)
stable over 2.5 h at physiological
temperature (37 8C), MB size decreased
rapidly to 1.3  0.4 mm within 50 min
[50]
Coaxial Outer nozzle: 2.2
Inner nozzle: 1.9
Air, BSA Biological
scaffolds
240–1000 Silk fibroin Silk fibroin was used to produce MBs that
exhibited unique morphology compared
with aqueous silk fibroin bubbles. The
resulting hollow spherical structures
could also serve as porous niches with
potential applications in tissue
engineering and bio-coatings
[52]
Coaxial Outer nozzle: 2.2
Inner nozzle: 1. 9
Air, BSA Biological
scaffolds,
sensors and
drug delivery
potetial
40–800 BSA, distilled
water-
glutaraldehyde,
glycerol and
glycerol-
TweenW 80
Increasing the flow rate of BSA solution
reduced the polydispersity of MBs and
stability test showed bubble size and size
distribution stability was enhanced over
time. However, MB stiffness increased
from 8 N/m to 20 N/m upon increasing
BSA concentration in the solution from
5 wt% to 15 wt%
[51]
Printing Single OD: 1.175
ID: 0.75
Nano-
hydroxyapatite
Biomedical
engineering
<5 PCL Direct writing of nano-hydroxyapatite
can be advantageous in biomedical
artificial tissue scaffolds. The pores on the
resulting tracks can yield various
degradation rates as well as diffusion of
various molecules from the polymeric
matrix
[58]
Single ID: 0.5 Tetracycline
hydrochloride
Antibacterial 0.7–5.0 PVP
PEO
PVP–PEO
Antibiotic drug was encapsulated within
various polymeric compositions with the
ability to control release. Relatively high
encapsulation achieved. Facile control on
patterning
[59]
Single OD: 0.320
ID: 0.05
Silver Antibacterial
potential
0.7 Silver NP ink Increased resolution in EHD printing by
utilizing a hypodermic needle
[54]
Single ID: 0.33 Copper oxide Antibacterial 50 PU Antibacterial activity (MRSA) using
polyurethane-copper oxide film
compositions (up to 10 w/w%) shown
[60]
Other
technology
Multi-needle
electrospinning
OD: 0.6
ID: 0.55
N/A N/A Down to 0.2 PEO Fiber diameter greatly reduced as the
number of needles used increased (1, 7,
37 needles). Hexagonal configuration of
needles yielded finer fibers owing to
more-uniform electric field at needle tips.
The more needles used the larger
collection distance was required
[41]
Triaxial
electrospinning
Core: OD: 0.55
ID: 0.3
Intermediate: OD: 1.25
ID: 0.85
Sheath: OD: 2.11
ID: 1.6
Keyacid blue,
keyacid uranine
Probe
(drug or
active delivery)
PCL, PVP Triaxial configuration of needles yielded
trilayered fibers that exhibited slower
release of probes; providing initial burst
release from hygroscopic PCL shell layer
and subsequent sustained release from
fiber core. The intermediate layer
provided an extra barrier to drug
diffusion and hence contributed to the
sustained release of probes
[43]
Needle-less
electrospinning
N/A N/A N/A 0.2–0.8 PEO Polymeric solution was directed onto a
metal roller spinneret; this method
proved to be 24–45-times more
productive than single needle
electrospinning
[44]
Aligned needles
(nonconcentric)
Not specified PTDPV-dye
ADS 306PT-dye
Probe
(drug or
active
delivery).
Targeted
delivery
0.423  0.291 PLGA,
CTAB, PMMA,
modfied PLGA
and PMMA
Janus particles formed through ‘co-
jetting’. Particles persisted in vivo (murine)
for over 24 h but also demonstrated
specific targeted capabilities
[48]
Abbreviations: OD, outer diameter; ID, inner diameter; ES, electrospinning; ESy, electrospraying; PCL, polycaprolactone; NPs, nanoparticles; NFs, nanofibers; PLGA, poly(lactic-co-glycolic
acid); PMMA, poly(methyl methacrylate); HCPT, hydroxycamptothecin; PVA, poly(vinyl alcohol); BSA, bovine serum albumin; MBs, microbubbles; PVP, polyvinyl pyrrolidone; MRSA,
methicillin-resistant Staphylococcus aureus; CTAB, cetyl trimethylammonium bromide; PEO, polyethylene oxide; PU, polyurethane; PEG, polyethylene glycol.
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(a) (b) (c)
(d) (e)
20 µm 5 µm 5 µm
20 µm 20 µm 20 µm
(f)
Drug Discovery Today 
FIGURE 2
Examples of structures generated using EHDA technologies showing (a) core–shell PCL microcapsules via coaxial electrospraying, (b) solid PLGA matrix-type
microparticles via single nozzle electrospraying, (c) PVP nanofibers via single-nozzle electrospraying, (d) BSA microbubbles via microbubbling, (e) PVP patterns via
printing and (f) PMSQ microtube bundles via coaxial electrospinning. Abbreviations: PVP, polyvinylpyrrolidone; PLGA, poly(lactic-co-glycolic acid); PCL,
polycaprolactone; PMSQ, polymethylsilsesquioxane; BSA, bovine serum albumin.
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min (BSA) or myoglobin] were engineered with different hydro-
philicities. Scaffolds (468  139 nm) exhibited appreciable (80%)
protein EE and also displayed potential for dual protein delivery
[11]. Luciferase (an oxidative enzyme) has also been loaded into
polyvinyl alcohol (PVA) fibers using a single nozzle system. Lucif-
erase retained its enzymatic activity after ES fabrication and con-
tinuous release of the enzyme from PVA nanofiber matrix was
shown [12].
DNA-based pharmaceuticals for the treatment of various dis-
eases (such as acute respiratory distress syndrome, asthma, cystic
fibrosis and cancer) have interestingly increased in number. Zeles-
Hahn et al. demonstrated the potential to administer DNA-based
therapeutics in the form of aerosols to the pulmonary system.
Naked and complexed plasmid DNA–polyethyleneimine aerosols
were fabricated using ESy (flow rate of 0.2 ml/min and applied
voltage range 0–6 kV) using a single nozzle system, with no
indication of structural alteration or loss of DNA integrity and
minimum cell toxicity [13].
One of the earliest studies that used ES for DNA-based applica-
tions transpired in the late 1990s, where calf-thymus Na-DNA
fibers (50 and 80 nm) were produced [14]. More recently, focus
has been directed toward the potential of encapsulating and
delivering siRNA because of extracellular limitations (degradation
and specific cell targeting) and intracellular limitations (endoso-
mal escape and mRNA targeting) [15]. Whereas therapeutic appli-
cations of siRNA are often in the form of NPs, for emerging
applications such as tissue regeneration electrospun fibers offer
a cost-effective and simple alternative to achieve encapsulation
and sustained activity. For example, electrospun siRNA-loaded
polycaprolactone (PCL) fibers (300–400 nm) demonstrated siRNA
release for 28 days at physiological conditions [16].The administration of anticancer drugs to a specific site of
action (to provide therapeutic effect) is often met with numerous
challenges. Physical properties (such as drug solubility and poor
drug pharmacodynamics) can prevent therapeutic drug concen-
trations from reaching the site of action, resulting in frequent
administration. Cyclophosphamide (INN) is an anticancer drug
that is used for the treatment of various cancer types such as
retinoblastoma, neuroblastoma and breast cancer. It functions
by disrupting DNA replication or can be combined with DNA
(combined therapy) to inhibit tumor growth [17].
Gulfam et al. synthesized a potent tool for the delivery of INN
with controlled-release properties. Gliadin NPs and gliadin–gela-
tin composite NPs loaded with INN were produced using the single
nozzle ESy technique. The loading efficiency of NPs was
72.02  5.6%. In comparison with gliadin–gelatin composite
NPs, gliadin NPs demonstrated a gradual drug release for 48 h
whereas gliadin–gelatin composite NPs showed a rapid drug re-
lease. Moreover, breast cancer cells cultured with 7% INN-loaded
gliadin NPs led to apoptosis after 24 h [18].
Silk-based NPs have been successfully developed to aid the
delivery of proteins, small molecules and APIs including antican-
cer drugs [19]. Silk fibroin, a naturally occurring protein, has been
used as a novel nanocarrier for anticancer drugs, engineered using
the EHDA process. To maintain the therapeutic activity of cis-
dichlorodiamminoplatinium (cisplatin), the active was loaded
into silk fibroin NPs by single nozzle ESy. NPs (59 nm in diame-
ter) demonstrated slow and sustained release of cisplatin for more
than 15 days whereas in vitro anticancer studies exhibited apopto-
sis of A549 lung cancer cells but showed weaker interactions with
normal healthy cells [20].
The EHDA process has also been used to vary polymorphic
forms of drugs. For example, piroxicam (polymorphic form I)www.drugdiscoverytoday.com 161
REVIEWS Drug Discovery Today  Volume 22, Number 1  January 2017
R
eview
s
P
O
S
T
S
C
R
E
E
Nwas dissolved in chloroform and then electrosprayed (flow rate
2.5–3.0 ml/h and applied voltage range 2.7–4.1 kV) using a
single nozzle system. The resulting polymorph displayed an
unknown crystal structure when examined using X-ray diffrac-
tion (XRD), Fourier transform infrared (FTIR) and Raman spec-
troscopy. Comparisons between FTIR spectra and XRD showed
evident changes in structure, new functional groups and chemi-
cal bonds. The particles (diameter 11.4 mm) were spherical in
shape and showed no signs of degradation over 127 days of storage
[21].
In recent times, pharmaceutical and biomaterial applications
have diversified and evolved for more-complex forms of dosage
development and delivery (e.g., multimodal drug action for par-
enteral delivery) [1,22]. For example, rapidly dissolving polyvinyl-
pyrrolidone (PVP) was used to develop double-sided coatings and
multifunctional contact lenses [1]. PVP NPs less than 100 nm in
size and PVP nanofibers (NFs) less than 200 nm in diameter were
utilized as active ocular lens coatings, demonstrating model probe
release and antibacterial properties.
Coaxial arrangement
Coaxial EHDA (co-EHDA) is the term used to describe the use of
two conductive nozzles in conjunction in a coaxial arrangement.
This configuration can be utilized for one-step encapsulation of
APIs and therapeutic agents within a polymeric shell or matrix.
The materials used within this system are ideally immiscible;
therefore, coaxially aligned nozzles produce particles with a de-
fined shell (polymer) and a defined core (therapeutic agent).
Loscertales et al. were the first to propose the use of coaxial nozzles.
Using a coaxial set-up, capsules (inner nozzle: water; outer nozzle:
olive oil) ranging in size between 150 nm and 10 mm were pro-
duced [23]. In the coaxial arrangement, the medium with greater
electrical conductivity is the driving force and, therefore, materials
possessing very low electrical conductivities can be engineered
using co-flow under an electrical field. Although the vast majority
of co-EHDA research has focused on two concentric nozzles, the
potential to use three or more [3,24] nozzles has also been dem-
onstrated for compartmentalization within particles for biomedi-
cal applications, including the use of multiple model materials and
phases.
Co-EHDA has been used to produce complex structures, encap-
sulating biomacromolecules such as peptides and proteins without
denaturation and degradation. For instance, angiotensin II was
successfully encapsulated into tristearin, yielding clear core–shell
NPs (diameter 100–300 nm) with EE of 92  1.8%. An in vitro
triphasic release profile was indicated [25]. Model protein BSA has
been encapsulated within a biodegradable PLGA shell yielding
particles with diameters between 3 and 5.5 mm. BSA EE was 15.7%
and 25.1% higher than emulsion ESy particles for high and low
molecular PLGA, respectively; indicating material properties (i.e.,
molecular weight) and processing variables can have a significant
effect on encapsulation of actives during the ESy process [26].
Laelorspoen et al. developed zein microparticles (MPs) consist-
ing of an alginate and Lactobacillus acidophilus core and acidified
zein (shell matrix) to assess the ability to produce EHDA engi-
neered vehicles for microorganism delivery. Here, core–shell struc-
tures provided sufficient protection from harsh physiological
conditions. The capsules (size range 543  88 to 259  62 mm162 www.drugdiscoverytoday.comdepending on the applied voltage) improved the survival of the
probiotic bacterium fivefold in stimulated gastric fluid [27].
Ongoing developments (and optimization) in EHDA processes
and careful selection of formulation materials has made the con-
cept of controlled production of miniaturized capsules a reality
[28–30]. Alginate micro- and nano-capsules (range 80 nm to
900 mm) were generated for the encapsulation of essential oils
[28]. Particles 60 nm in size loaded with metronidazole were also
synthesized using the co-EHDA process. The antimicrobial, anti-
protozoal agent was loaded into Eudragit1 RS/poly(methyl meth-
acrylate) (PMMA) core–shell particles at an applied voltage of
15 kV. The amphiphilic (hydrophobic shell, hydrophilic core)
metronidazole nanocapsules exhibited EE of 100.2  0.92% by
using 2% PMMA. Porous amphiphilic NPs have potential to be
used in various clinical and pharmaceutical applications encapsu-
lating a variety of therapeutic agents, especially where two sepa-
rate phases are needed [29]. Where this is not essential, multiple
actives can be encapsulated into a composite system. For example,
dual drug release has been demonstrated using PVP–PLGA and
PCL–PLGA composites. NPs (with EE of >85%) of hydrophilic
rhodamine B and hydrophobic naproxen were synthesized [30].
Although matrix-type encapsulation of anticancer drugs is
achievable using single nozzle systems, co-EHDA provides more-
complex structures (e.g., layering) for encapsulation. For example
the generation of core–shell fibers encapsulating anticancer drugs
has exhibited controlled and sustained drug release and has dem-
onstrated prohibition of cancer cell attachment and proliferation
[31,32]. Yang et al. developed an implantable device that exploited
the amphiphilic nature of micelles and broad application of
polymeric NFs. Hydrophobic doxorubicin was entrapped into
micelles which formed the core of gelatin fibers along with
PVA. The development of this biodegradable device reduced the
drug dose required to be administered as well frequent adminis-
tration, while providing sufficient therapeutic effect against
cancerous tissue [32].
The co-EHDA process can also be used for the advanced delivery
of anti-inflammatories. Ibuprofen (IBU) delivery systems have
been developed as triple-component nanocomposites [33] and
NFs [34]. Zein (a prolamine protein) was used to distribute ibupro-
fen (the core) evenly into N,N-dimethylformamide fibers [34].
Qian et al. developed triple-component nanocomposites [IBU-
PVA-polyacrylonitrile (PAN)] possessing mean diameters of
620 120 nm with 10.5% PVP content. Compared with double-
component nanocomposites (IBU–PAN), the triple-component
structures significantly improved in vitro IBU release kinetics,
preventing IBU immobilization within insoluble PAN molecules
[33].
BSA has been frequently used as a model protein to demonstrate
the delivery of proteins using co-EHDA [11,35]. Electrospun fi-
brous scaffolds have been developed in which two proteins have
been incorporated to provide structural support as well as to
stimulate tissue regeneration. BSA and myoglobin were separately
integrated into PLGA–Pluronic1 F-127 fibrous scaffolds
(423  209 nm) with a loading efficiency of 80%; proving to
be a useful dual protein delivery system for tissue engineering
applications [11]. More recently, electrospun poly(L-lactic acid)
(PLLA)–gum-tragacanth NFs were developed that exhibited prom-
ising capabilities as grafts for nerve tissue regeneration, high cell
Drug Discovery Today  Volume 22, Number 1  January 2017 REVIEWS
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tragacanth increased hydrophilicity of PLLA scaffolds as well as NF
diameter (226  73 nm) as a result of increased electrical conduc-
tivity [36].
Many co-axial studies have focused on the generation of a core–
shell, which will impact the release or encapsulation of active (e.g.,
drug). Therefore, the ability to control shell thickness is crucial in
developing tailored therapies. Gao et al. have prepared PCL-shell
MPs, encapsulating hydrophobic Sudan Red (a model hydropho-
bic active in a silicone oil solution) [37]. The resultant structures
(30–70 mm) had controllable shell-thickness:radius (T:R) ratios
and exhibited initial burst release followed by sustained release,
tunable by the T:R ratio. The ability to encapsulate actives within a
polymeric shell using a coaxial set up is further advantageous for
the delivery of oil-based materials or hydrophobic actives, which
cannot be achieved using such materials alone.
Shell material variation in EHDA engineered structures enables
the development of stimuli-responsive materials (e.g., through
external triggers), which are gaining interest in biomedical engi-
neering. However, encapsulation of non-polymeric functional
materials has advanced the field further. For example, Wang
et al. have prepared hollow PCL fibers encapsulated with magnetic
Fe3O4 and antifungal drug in the core–shell matrix [38]. The
application of an external auxiliary magnetic field enhanced drug
release, with the potential to control drug release in situ as an on-
demand process. Furthermore, the embedded magnetic particles
are also able to provide imaging potential. Using similar magnetic
NPs and fluorescent dye for encapsulation, red-blood-cell-like
polymer particles were engineered using a single nozzle ESy pro-
cess. Here, dual imaging modality was shown for dark [magnetic
resonance imaging (MRI)] and fluorescing phases [39].
Complex multiple nozzle systems
Advances in EHDA methods have extended toward the develop-
ment of multi-nozzle or emitter devices that are able to produce
particles and fibers in greater capacity and/or complexity [40]. The
use of several nozzles and syringes within the process allows the
fabrication of fibrous mats such as tissues from multi-jets (Fig. 1f).
This system is more complex than single nozzle or coaxial (two
nozzles) processes owing to the repulsion that is induced between
similarly charged jets. Multi-nozzle systems require a well thought
out configuration of nozzles to optimize ES and ESy productivity.
Nozzles can be configured in various geometries for example
circular, triangular or hexagonal as demonstrated by Yang et al.
[41]. Preliminary simulation studies showed that using outer
nozzles in a hexagonal format assisted in the creation of a uniform
electric field near the tips of nozzles, yielding finer polyethylene
oxide (PEO) fibers (down to 200 nm) [41].
Biodegradable multilayered NFs have been fabricated by Liu
et al. using a triaxial (three nozzle) ES set-up [42]. PCL (intermedi-
ate layer) and gelatine (sheath and core) were electrospun and
fibers of 25 mm were generated, showing the ability to manufac-
ture multilayered NFs with various applications in biotechnology
[42]. Triaxial NFs were utilized to demonstrate release profile
control of separately encapsulated model drugs (color dyes: key-
acid blue and keyacid uranine). PCL and PVP were used to produce
triaxial NFs demonstrating sustained release of probes, which was
24-times slower than the release of the same drugs from fibersproduced using coaxial ES. Moreover, triaxial NFs are effective in
providing short-term treatment by rapid release of drug entrapped
in the outer sheath layer and also for long-term treatment, via
sustained release, of drug entrapped in the fiber core [43].
A novel approach for ES was developed by Yarin and Zussman,
utilizing a nozzle-less system with a magnetic suspension and
magnetic field to force the suspension through a polymer solution,
resulting in NFs that ranged from 200 to 800 nm in size. Perturba-
tion of the polymer layer by the ferromagnetic suspension led to a
12-fold enhancement of the production rate of the ES process [44].
Bocanegra et al. also developed a nozzle-less system that used
orifices rather than nozzle capillaries to achieve a steady jet for
atomization of liquids [45]. The system (consisting of up to 37
pores) was found to increase the stability and reliability of the
EHDA process. The orifices were arranged in a planar hexagonal
pattern with each delivering a cone-jet in the multispray system,
which behaved independently from adjacent jets. The multipore
system was electrically stable, regardless of pore number or orifice
diameter. Jet-bending (from electrostatic interactions with neigh-
boring jets) has been demonstrated using a flute-like horizontal
device for the high-throughput production of PCL MPs [46]. The
novel device utilized a multipore design instead of nozzle capillar-
ies where modifying pore configuration and processing parameters
(applied voltage) yielded uniform MPs. The spatial location of
these multiple pores was found to have adverse effects on the
stability of the jets; electrostatic forces between adjacent jets
caused the jets to bend, generating particles with irregular
morphologies. By manipulating the spatial locations, these incon-
sistencies in morphology can be overcome.
Another recent development has moved away from concentric
nozzles and focused more on aligned or converging nozzles (also
termed co-jetting). Here, atomized materials do not encapsulate
one another but rather form composites as segmented compart-
ments. These have been useful for the preparation of several Janus
particle systems, which are able to combine functional properties
through precursor spraying (for further processing) [47] as well as
altering the shape and segment loading volume, which has great
potential in targeted drug delivery [48].
Microbubbles (MBs; hollow MPs filled with air) have been
developed and utilized in a vast array of applications in the
pharmaceutical industry (e.g., ultrasound imaging and biomedical
engineering) [49] and their engineering using EHDA provides
potential to modify their properties (e.g., drug loading and coating
layer type and number) [3] in situ during synthesis. Farook et al.
utilized a coaxial set-up for the production of MB suspensions with
MBs possessing biocompatible phospholipid coatings. These MBs
were produced at high yield rates (109 bubbles/min) and were
found to decrease in size at physiological temperature. The size
and shape alleviated and maintained shape at 1–2 mm after
20 min, showing an increase in temperature led to an increase
in the diffusion of air through the phospholipid shell [50].
Coaxial configuration of EHDA has also been used to develop
protein (BSA) MBs and porous films [51,52] suggesting a novel tool
for protein and peptide applications. A combination of high yield
and uniform production with easily amendable size modifications
show the potential for multiple biomedical applications including
tissue engineering. For example, Ekemen et al. developed silk
fibroin bubbles (240–1000 mm) with hollow spherical structureswww.drugdiscoverytoday.com 163
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advantageous in bio-coatings and tissue engineering [52]. Near
mono-dispersed BSA-loaded MBs ranging from 40 to 800 mm have
been produced that exhibited negligible changes in size over time
which could be due to unfolding of BSA within the bubbles or the
solvent evaporation rate [53]. These stabilized MBs can be utilized
in vital clinical applications such as protein delivery and tissue
engineering.
Electrohydrodynamic jet printing and patterning
Electrohydrodynamic jet (E-Jet) printing is a manufacturing pro-
cess that can ‘print’ or ‘write’ patterns on various surfaces on
micro- and nano-scales [54]. E-Jet printing utilizes an electrical
field to drive jet printing through conductive nozzles, allowing the
printing process to be controlled by altering the voltage potential.
Ions available in the ejected solution are attracted toward a sub-
strate with the aid of the electrical field. This causes the cone jet to
deform leading to instability, releasing droplets at the cone apex.
There are currently two recognized modes of E-Jet printing: on
demand and continuous. Demand mode revolves around the
concept of controlling the jet production and emission only
occurs when needed at a pulsed applied voltage, resulting in high
deposition accuracy. Continuous jet printing utilizes a pulsed
voltage, which can subsequently cause destabilization of the cone
jet. E-Jet devices use significantly larger capillary nozzles (com-
pared with conventional systems) that can help reduce any capil-
lary blockage leading to easier processing of solutions, especially
suspensions or viscous liquids [55].
A range of biomaterials have been fabricated using E-Jet print-
ing. Hydroxyapatite (HA) NPs were suspended in an ethanol-based
suspension and subjected to an electric field. The droplets were
deposited according to a programmed topography, yielding pat-
terned tracks as small as 50 mm in width. The utilization of HA-NPs
has also extended to the regulation of human osteoblast cell
attachment and orientation and also has potential in osteocon-
duction of implants [56].
The capabilities of this technology have also extended to
forming or producing architectures for tissue and biomedical164 www.drugdiscoverytoday.comengineering. Nanocomposite biopolymer (polyurethane system
containing silicon components for enhanced surface properties)
scaffolds for potential organ development were generated. A 3D
EHDA print-patterning device yielded threads less than 50 mm
according to a predetermined pattern [57], whereas direct printing
of PCL with nano-HA nanocomposites deposited smaller (less than
5 mm), pre-determined structures; and this could be very advanta-
geous in biomedical topographical engineering [58]. More-recent
developments have seen EHDA printing of drug (antibiotic tetra-
cycline hydrochloride) loaded PVP composite fibers demonstrat-
ing the ability to develop personalized dosage forms without the
use of numerous excipients and formulation steps [59]. There is
also potential to utilize functional materials that have deposited
using EHDA printing but not been explored in great depth for their
biological properties (e.g., as antibacterial coatings) [60]. For ex-
ample, silver NP ink was used as a jetting solution via slanted
hypodermic needles. The utilization of slanted nozzles in place of
flat orifices increased the resolution in EHD printing with the
narrowest line being printed possessing a width of 0.7 mm [61].
Silver nanowires have also been used for E-Jet printing. Here, the
mechanical stretching of the jet solution and enhanced electro-
static forces resulted in highly aligned wires on a nanoscale [62].
Concluding remarks
From the atomization of simple solution droplets to 3D printing,
developments in EHDA technologies can uniquely facilitate devel-
opments in numerous pharmaceutical and biomaterial remits.
Furthermore, recent developments have shown significant scale-
up potential (kg/h production rates), which adds to existing
advantageous properties of these high value technologies (e.g.,
controlled deposition, ambient condition operation, complex
structure generation and digital engineering) over existing con-
ventional methods.
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